Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ system. The clearance marks the final
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
As of April 3, 2026, Medtronic plc (NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the Dublin-based medical technology giant is currently navigating the final stages of a profound structural transformation. With the recent partial IPO of its diabetes [...]
NEW YORK — The global mergers and acquisitions (M&A) market has entered a period of unprecedented expansion in the first half of 2026, marking a definitive end to the "deal desert" of previous years. Driven by a surge in private equity confidence—now reaching a staggering 86%—and a landmark
The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided the market with a compelling case study in strategic resilience. Reporting its third-quarter fiscal 2026 results, the company showcased
The first quarter of 2026 has signaled a definitive end to the "deal drought" that plagued the previous three years, as American corporations embark on an unprecedented wave of consolidation. Driven by a hunger for artificial intelligence (AI) infrastructure, a stabilizing interest rate environment, and landmark tax legislation, the U.
As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of the healthcare sector, Medtronic has spent the last three years in the throes of a massive structural and cultural overhaul. Today, [...]
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed its legacy consumer health business and weathered the initial storm of its largest patent cliff in a decade, J&J has rebranded itself as a [...]
Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its Pulsed Field Ablation (PFA) portfolio, the stock is experiencing a sharp intraday decline of 4.2% today, March 31, 2026. This move comes despite the recent [...]
Check out the companies making headlines yesterday: Avis Budget Group (NASDAQ:CAR): Car rental services provider Avis (NASDAQ:CAR) fell by 9% on Monday after...
What Happened? Shares of medical device company Boston Scientific (NYSE:BSX) fell 9.4% in the afternoon session after Raymond James downgraded the stock to O...
The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous years. As of late March, total announced deal volume has surged past the $1 trillion milestone, a 27%
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic $813.3 billion, a massive 50% increase over the same period last year. This record-breaking figure
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of the past for targeted,
